Search results for "clinical research"

showing 10 items of 474 documents

Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pand…

2021

Abstract Background Surgical services are preparing to scale up in areas affected by COVID-19. This study aimed to evaluate the association between preoperative SARS-CoV-2 testing and postoperative pulmonary complications in patients undergoing elective cancer surgery. Methods This international cohort study included adult patients undergoing elective surgery for cancer in areas affected by SARS-CoV-2 up to 19 April 2020. Patients suspected of SARS-CoV-2 infection before operation were excluded. The primary outcome measure was postoperative pulmonary complications at 30 days after surgery. Preoperative testing strategies were adjusted for confounding using mixed-effects models. Results Of 8…

Lung DiseasesMalexAcademicSubjects/MED00910COVID-19/diagnosisSettore MED/18 - CHIRURGIA GENERALEneoplasms030230 surgeryminorsurgical proceduresMedical and Health SciencesLung Disease0302 clinical medicinePostoperative Complications030202 anesthesiologyaged; aged 80 and over; COVID-19; elective surgical procedures; female; humans; lung diseases; male; middle aged; Nasopharynx; neoplasms; pandemics; postoperative complications; risk assessment; SARS-CoV-2; COVID-19 nucleic acid testingNeoplasmsNasopharynx80 and over030212 general & internal medicine610 Medicine & healthLungCancerlung diseasesAged 80 and overIncidence (epidemiology)ConfoundingPulmonary ComplicationLung Diseases/*etiologyNeoplasms/surgeryGeneral MedicineMiddle AgedElective Surgical Procedures/adverse effectsOncologyElective Surgical Procedures030220 oncology & carcinogenesisCOVID-19 Nucleic Acid TestingOriginal ArticleFemalePatient SafetyAcademicSubjects/MED00010Elective Surgical Procedure6.4 SurgeryHumanCohort studymedicine.medical_specialtypreoperative caresurgical proceduresCOVID-19 nucleic acid testing.elective surgical proceduresPreoperative careRisk AssessmentArticleCOVIDSurg CollaborativeNO*COVID-19 Nucleic Acid TestingVaccine Related03 medical and health sciencesClinical ResearchBiodefensemedicineNasopharynx/*virologyHumansNasopharynx/virologyElective surgeryAdverse effectPandemicsLS7_4AgedElective Surgical ProcedurePandemicbusiness.industrySARS-CoV-2Surgery Sars Cov2PreventionNo key words availableelectivesurgical proceduresLung Diseases/etiologyEvaluation of treatments and therapeutic interventionsCancerPostoperative complicationoperativenasopharynxsurgery specialtypulmonary complicationscancer surgerysars-cov-2covid-19coronavirus pandemicCOVID-19Odds ratiomedicine.diseaseConfidence intervalSurgeryCOVID-19/*diagnosisEmerging Infectious DiseasesGood Health and Well BeingNeoplasmSurgeryPostoperative Complicationpreoperative caresurgical procedures electivesurgical procedures minorsurgical procedures operativenasopharynxsurgery specialtypulmonary complicationscancer surgerysars-cov-2covid-19coronavirus pandemicElective Surgical Procedures/*adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Le strategie comunicative di Cosa nostra: una ricerca empirica

2014

The following article proposes an empirical study to explore communication strategies in Cosa Nostra. Psychological studies on the characteristics of the language used within the criminal organization are undoubtedly recent, but crucial to thoroughly understand the characteristics of the implicit and explicit communication it adopts in the various contexts it works, as well as the power and value they assume. The data we have obtained from some videos concerning interviews and police interrogations to men of honor have been analyzed through a method which refers to the grounds of qualitative research in clinical psychology, the Grounded Theory (Glaser, Strauss; 1967). The analysis we have c…

Mafia language clinical research in the social field
researchProduct

Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven In…

2020

Objective To characterize the ecological effects of biologic therapies on the gut bacterial and fungal microbiome in psoriatic arthritis (PsA)/spondyloarthritis (SpA) patients. Methods Fecal samples from PsA/SpA patients pre- and posttreatment with tumor necrosis factor inhibitors (TNFi; n = 15) or an anti-interleukin-17A monoclonal antibody inhibitor (IL-17i; n = 14) underwent sequencing (16S ribosomal RNA, internal transcribed spacer and shotgun metagenomics) and computational microbiome analysis. Fecal levels of fatty acid metabolites and cytokines/proteins implicated in PsA/SpA pathogenesis or intestinal inflammation were correlated with sequence data. Additionally, ileal biopsies obtai…

Male0301 basic medicineArthritisPsoriatic0302 clinical medicineInterleukin 25Monoclonal2.1 Biological and endogenous factorsImmunology and AllergyMedicineAetiologyIntestinal MucosaCandida albicansHumanizedSubclinical infectionbiologyInterleukin-17Innate lymphoid cellMiddle AgedIntestinesPublic Health and Health ServicesFemaleTumor necrosis factor alphaInterleukin 17Clinical SciencesImmunologyAntibodies Monoclonal HumanizedAutoimmune DiseaseAntibodiesArticle03 medical and health sciencesRheumatologyClinical ResearchSpondylarthritisHumansMicrobiomeInflammation030203 arthritis & rheumatologybusiness.industryArthritisInflammatory and immune systemArthritis Psoriaticbiology.organism_classificationmedicine.diseaseArthritis & RheumatologyGastrointestinal Microbiome030104 developmental biologyImmunologyTumor Necrosis Factor InhibitorsDigestive Diseasesbusiness
researchProduct

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

2021

Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic mod…

Male0301 basic medicineDimethyl FumarateNeurodegenerativemultiple sclerosis; coronavirus; pneumoniaSeverity of Illness Indexlaw.inventionImmunosuppressive AgentImmunologic Factor0302 clinical medicineNatalizumablawMonoclonalMultiple Sclerosi80 and overLungHumanizedResearch ArticlesAged 80 and overNatalizumabMiddle AgedIntensive care unitHospitalizationSettore MED/26 - NEUROLOGIAIntensive Care UnitsNeurologyMethylprednisoloneNeurologicalPneumonia & InfluenzaInterferonFemaleImmunosuppressive AgentsResearch ArticleHumanmedicine.drugAdultmedicine.medical_specialtyMusc-19 Study GroupMultiple SclerosisAdolescentClinical SciencesIntensive Care UnitClinical NeurologySettore MED/26Antibodies Monoclonal HumanizedAutoimmune DiseaseAntibodiesYoung Adult03 medical and health sciencesClinical ResearchInternal medicineSeverity of illnessmedicineHumansImmunologic FactorsMortalityAdolescent; Adult; Aged; Aged 80 and over; Antibodies Monoclonal Humanized; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Immunologic Factors; Immunosuppressive Agents; Intensive Care Units; Interferons; Male; Middle Aged; Mortality; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Severity of Illness Index; Young AdultAgedNeurology & NeurosurgeryExpanded Disability Status ScaleFingolimod HydrochlorideSARS-CoV-2business.industryMultiple sclerosisNeurosciencesCOVID-19PneumoniaOdds ratiomedicine.diseaseBrain DisordersGood Health and Well Being030104 developmental biologyOcrelizumabInterferonsNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Corticotroph aggressive pituitary tumours and carcinomas frequently harbour ATRX mutations

2021

Abstract Context Aggressive pituitary tumors (APTs) are characterized by unusually rapid growth and lack of response to standard treatment. About 1% to 2% develop metastases being classified as pituitary carcinomas (PCs). For unknown reasons, the corticotroph tumors are overrepresented among APTs and PCs. Mutations in the alpha thalassemia/mental retardation syndrome X-linked (ATRX) gene, regulating chromatin remodeling and telomere maintenance, have been implicated in the development of several cancer types, including neuroendocrine tumors. Objective To study ATRX protein expression and mutational status of the ATRX gene in APTs and PCs. Design We investigated ATRX protein expression by us…

Male0301 basic medicineEndocrinology Diabetes and MetabolismClinical Biochemistrypituitary adenomapituitary carcinomaBiochemistryPATHWAYCohort Studies0302 clinical medicineEndocrinologyGene FrequencyTELOMERESCorticotrophsClinical Laboratory MedicineGenomicsMiddle AgedCushing’s diseaseEUROPEAN-SOCIETY3. Good healthEuropeKlinisk laboratoriemedicinACTH-Secreting Pituitary Adenoma030220 oncology & carcinogenesisDAXX/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingCushing's diseaseFemaleATRX (alpha thalassemia/mental retardation syndrome X-linked); aggressive PitNETs; pituitary carcinoma; pituitary adenoma; Cushings diseaseAcademicSubjects/MED00250EXPRESSIONAdenomaAdultX-linked Nuclear Proteinmedicine.medical_specialtyGENESAdolescentATRX (alpha thalassemia/mental retardation syndrome X-linked)3122 CancersNonsense mutationContext (language use)CLASSIFICATIONYoung Adult03 medical and health sciencesDeath-associated protein 6SDG 3 - Good Health and Well-beingPituitary adenomaInternal medicineADENOMASmedicineHumansGenetic Predisposition to DiseaseNeoplasm InvasivenessPituitary NeoplasmsClinical Research ArticlesATRXAgedCancer och onkologiaggressive PitNETsbusiness.industryCarcinomaBiochemistry (medical)Pituitary tumorsCancerAMPLIFICATIONNeuroendocrinologymedicine.disease030104 developmental biologyEndocrinologyPituitary3121 General medicine internal medicine and other clinical medicineCancer and OncologyMutationPituitary carcinomaCancer researchbusinessATRX (alpha thalassemia/mental retardation syndrome X-linked); Cushing’s disease; aggressive PitNETs; pituitary adenoma; pituitary carcinoma
researchProduct

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis

2018

ObjectivePrimary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic contribution to the severity and progression of PSC. The aim of this study is to identify genetic variants associated with PSC disease progression and development of complications.DesignWe collected standardised PSC subphenotypes in a large cohort of 3402 patients with PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients—obtained using the Illumina immunochip—with their disease subphenotypes. Using logistic regression and Cox proportiona…

Male0301 basic medicineOncologyCandidate geneCholangitismedicine.medical_treatmentMedizinTrasplantament hepàticGenome-wide association studyKaplan-Meier EstimateLIVER FIBROSISLiver transplantationBioinformaticsSclerosingOral and gastrointestinalPrimary sclerosing cholangitis; genetics; liver transplantationCohort StudiesACTIVATION0302 clinical medicineMED/12 - GASTROENTEROLOGIAMULTIPLE2.1 Biological and endogenous factorsEPIDEMIOLOGYgeneticsAetiologyCIRRHOSISliver transplantationBilious diseases and biliousnessPrimary sclerosing cholangitisLiver Diseasedigestive oral and skin physiologyGastroenterologySingle NucleotidePrimary sclerosing cholangitiMiddle Aged3. Good healthULCERATIVE-COLITISDisease ProgressionFemale030211 gastroenterology & hepatologyAdultmedicine.medical_specialtyCholangitis SclerosingChronic Liver Disease and CirrhosisClinical SciencesMalalties del tracte biliarSingle-nucleotide polymorphismHEPATIC STELLATE CELLSPolymorphism Single NucleotideInternational PSC Study GroupArticlePrimary sclerosing cholangitisPaediatrics and Reproductive Medicine03 medical and health sciencesRare DiseasesClinical ResearchInternal medicineGeneticsmedicineHumansPolymorphismGENOME-WIDE ASSOCIATIONAlleleDigestive Diseases - (Gallbladder)Survival analysisProportional Hazards ModelsMALIGNANCYThe UK PSC ConsortiumTransplantationGastroenterology & Hepatologybusiness.industryProportional hazards modelmedicine.diseaseRISK LOCILogistic Models030104 developmental biology3121 General medicine internal medicine and other clinical medicinegeneticHepatic transplantationThrombospondinsDigestive DiseasesbusinessGenèticaGut
researchProduct

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multice…

2018

Summary Background Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAF V600 -mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoint of overall survival. Methods COLUMBUS was a two-part, randomised, open-label, phase 3 study done at 162 hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma, BRAF V600E or BRAF V600K mutation, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and were treatment naive or had pr…

Male0301 basic medicineOncologySkin NeoplasmsTime FactorsMedizinPhases of clinical researchGene mutationchemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsVemurafenibMelanomaAged 80 and overTrametinibSulfonamides10177 Dermatology ClinicBinimetinibMiddle AgedProgression-Free SurvivalPhenotypeOncologyTolerability030220 oncology & carcinogenesisDisease ProgressionFemale2730 Oncologymedicine.drugAdultProto-Oncogene Proteins B-rafmedicine.medical_specialty610 Medicine & healthYoung Adult03 medical and health sciencesInternal medicineBiomarkers TumormedicineHumansGenetic Predisposition to DiseaseProgression-free survivalProtein Kinase InhibitorsAgedPerformance statusbusiness.industry030104 developmental biologyVemurafenibchemistryMutationBenzimidazolesCarbamatesbusinessThe Lancet Oncology
researchProduct

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma : an international, randomised, open-label, phase 3 study

2016

Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma.This randomised, open-label, multicentre, phase 3 clinical trial enrolled patients with relapsed or refractory mantle-cell lymphoma confirmed by central pathology in 21 countries who had received one or more rituximab-containing treatments. Patients were stratified by previous therapy and simplified mantle-cell lymphoma international prognostic index…

Male0301 basic medicineOncologymedicine.medical_specialtyPhases of clinical researchAntineoplastic AgentsKaplan-Meier EstimateLymphoma Mantle-Cell03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternational Prognostic IndexPiperidinesRecurrenceInternal medicinemedicineHumansAgedNeoplasm StagingAged 80 and overSirolimusbusiness.industryBortezomibAdenineGeneral MedicineMiddle AgedTemsirolimusSurgeryClinical trialPyrimidinesTreatment Outcome030104 developmental biologyTolerabilitychemistry030220 oncology & carcinogenesisIbrutinibRefractory Mantle Cell LymphomaPyrazolesFemalebusinessmedicine.drug
researchProduct

Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic th…

2017

// Gemma Bruera 1, 2 , Antonio Russo 3 , Antonio Galvano 3 , Sergio Rizzo 3 and Enrico Ricevuto 1, 2 1 Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy Correspondence to: Antonio Russo, email: antonio.russo@usa.net Keywords: elderly, intensive treatment, metastatic colorectal cancer, triplet chemotherapy plus bevacizumab, unfit Received: June 07, 2016     Accepted: November 24, 2016     Published:…

Male0301 basic medicineUnfitmedicine.medical_specialtyBevacizumabColorectal cancerDecision MakingAngiogenesis InhibitorsNeutropeniamedicine.disease_cause03 medical and health sciences0302 clinical medicineElderlyInternal medicinemedicineMucositisHumansNeoplasm MetastasisAgedRetrospective StudiesTriplet chemotherapy plus bevacizumabbusiness.industryMetastatic colorectal cancerelderly; intensive treatment; metastatic colorectal cancer; triplet chemotherapy plus bevacizumab; unfitRetrospective cohort studymedicine.diseaseComorbiditySurgeryRegimenTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleIntensive treatmentKRASClinical Research PaperColorectal NeoplasmsbusinessElderly; Intensive treatment; Metastatic colorectal cancer; Triplet chemotherapy plus bevacizumab; Unfit; Oncologymedicine.drug
researchProduct

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

2016

Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; BACKGROUND Chronic graft-versus-host disease (GVHD) is the leading cause of later illness and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that the inclusion of antihuman T-lymphocyte immune globulin (ATG) in a myeloablative conditioning regimen for patients with acute leukemia would result in a significant reduction in chronic GVHD 2 years after allogeneic peripheral-blood stem-cell transplantation from an HLA-identical sibling. METHODS We conducted a prospective, multicenter, open-label, randomized phase 3 study of ATG as part of …

Male:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models Statistical::Proportional Hazards Models [Medical Subject Headings]T-LymphocytesPhases of clinical researchGraft vs Host Disease:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]Linfocitos t:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Immunosuppressive Agent0302 clinical medicineTrasplante homólogoEstudios prospectivosMedicineCumulative incidenceProspective StudiesProspective cohort studyChildTransplantation Homologou:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Immune Sera::Antilymphocyte Serum [Medical Subject Headings]Acute leukemia:Anatomy::Cells::Blood Cells::Leukocytes::Leukocytes Mononuclear::Lymphocytes::T-Lymphocytes [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [Medical Subject Headings]:Named Groups::Persons::Age Groups::Child::Child Preschool [Medical Subject Headings]Medicine (all)IncidenceSuero antilinfocíticoGeneral MedicineMiddle AgedModelos de riesgos proporcionales3. Good healthHumanosSurvival Rate030220 oncology & carcinogenesis:Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings]Child PreschoolFemale:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents [Medical Subject Headings]Immunosuppressive AgentsHumanHomologousAdultmedicine.medical_specialty:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings]:Named Groups::Persons::Age Groups::Adult::Young Adult [Medical Subject Headings]AdolescentEnfermedad injerto contra huéspedDisease-Free Survival03 medical and health sciencesYoung AdultInternal medicine:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]HumansTransplantation HomologousSupervivencia sin enfermedadPreschoolSurvival rate:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free Survival [Medical Subject Headings]:Named Groups::Persons::Age Groups::Child [Medical Subject Headings]Antilymphocyte SerumProportional Hazards ModelsTransplantationbusiness.industryEnfermedad crónicamedicine.diseaseInmunosupresoresAnti-thymocyte globulinSurgeryTransplantation:Diseases::Immune System Diseases::Graft vs Host Disease [Medical Subject Headings]Prospective Studie:Analytical Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures Operative::Transplantation::Transplantation Homologous [Medical Subject Headings]Graft-versus-host diseaseT-Lymphocyte:Check Tags::Female [Medical Subject Headings]Chronic DiseaseProportional Hazards ModelAdolescent; Adult; Antilymphocyte Serum; Child; Child Preschool; Chronic Disease; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Survival Rate; T-Lymphocytes; Transplantation Homologous; Young Adult; Medicine (all)business030215 immunology
researchProduct